We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00455494
Recruitment Status : Unknown
Verified April 2007 by Tulane University Health Sciences Center.
Recruitment status was:  Recruiting
First Posted : April 3, 2007
Last Update Posted : April 3, 2007
Sponsor:
Collaborator:
Centers for Disease Control and Prevention
Information provided by:
Tulane University Health Sciences Center

Brief Summary:
The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.

Condition or disease Intervention/treatment Phase
Malaria Drug: AQ-13 Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial
Study Start Date : March 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria
U.S. FDA Resources




Primary Outcome Measures :
  1. Area under the time-concentration curve
  2. Maximal blood concentration
  3. Adverse events

Secondary Outcome Measures :
  1. Effect on heart repolarization (QTc interval change)
  2. Clearance
  3. Terminal elimination half-life


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers 21-45 years of age taking no chronic medications other than birth-control pills

Exclusion Criteria:

  • Pregnancy,
  • Breast-feeding,
  • Chronic disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00455494


Contacts
Contact: Fawaz Mzayek, MD, PhD 504-988-1062 fmzayek@tulane.edu

Locations
United States, Louisiana
Tulane-LSU General Clinical Research Center Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Fawaz Mzayek, MD, PhD    504-988-1062    fmzayek@tulane.edu   
Principal Investigator: Donald J Krogstad, MD         
Sponsors and Collaborators
Tulane University Health Sciences Center
Centers for Disease Control and Prevention
Investigators
Principal Investigator: Donald J Krogstad, MD Tulane University Health Sciences Center

Publications:
ClinicalTrials.gov Identifier: NCT00455494     History of Changes
Other Study ID Numbers: K0154-2
UR3/CCU 418652
U01CI000211 ( U.S. NIH Grant/Contract )
First Posted: April 3, 2007    Key Record Dates
Last Update Posted: April 3, 2007
Last Verified: April 2007

Keywords provided by Tulane University Health Sciences Center:
Drug-resistant malaria
Bioavailability
Food-effect study

Additional relevant MeSH terms:
Malaria
Protozoan Infections
Parasitic Diseases
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents